|
Sep 04, 2024
|
Innoviva to Participate in Upcoming Investor Conferences
|
|
|
Jul 31, 2024
|
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
|
|
|
Jun 03, 2024
|
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
|
|
May 20, 2024
|
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
|
|
|
May 08, 2024
|
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
|
|
|
May 08, 2024
|
Innoviva to Participate in the BofA Securities Health Care Conference
|
|
|
Apr 24, 2024
|
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
|
|
|
Mar 04, 2024
|
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
|
|
|
Feb 29, 2024
|
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
|
|